Sustained release formulations

Details Sustained release formulations Sustained release formulations

2007-08-30

2010-06-08

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S015800, C514S785000

Reexamination Certificate

active

07732399

ABSTRACT:
The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is epigallocatechin gallate (EGCG).

REFERENCES:
patent: 2849370 (1958-08-01), Petersen et al.
patent: 5019400 (1991-05-01), Gombotz et al.
patent: 5151265 (1992-09-01), Hwang-Felgner et al.
patent: 5192741 (1993-03-01), Orsolini et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5922253 (1999-07-01), Herbert et al.
patent: 5962522 (1999-10-01), Wacher et al.
patent: 5981474 (1999-11-01), Manning et al.
patent: 6180666 (2001-01-01), Wacher et al.
patent: 6428818 (2002-08-01), Morre et al.
patent: 6531154 (2003-03-01), Mathiowitz et al.
patent: 6613358 (2003-09-01), Randolph et al.
patent: 6759064 (2004-07-01), Morre et al.
patent: 7323169 (2008-01-01), Goldenberg et al.
patent: 2002/0119946 (2002-08-01), Gen
patent: 2002/0151582 (2002-10-01), Dou et al.
patent: 2003/0190307 (2003-10-01), DiBiase et al.
patent: 2004/0142048 (2004-07-01), Moore et al.
patent: 2005/0180925 (2005-08-01), Chaudry
patent: 2005/0215470 (2005-09-01), Ng et al.
patent: 929405 (1963-06-01), None
patent: 1234805 (1971-06-01), None
patent: WO 94/08599 (1994-04-01), None
patent: WO 98/10649 (1998-03-01), None
patent: WO 99/04764 (1999-02-01), None
patent: WO 00/51643 (2000-09-01), None
patent: WO 01/32218 (2001-05-01), None
patent: WO 2004/012522 (2004-02-01), None
Yan et al. Identification of histatins as tannin-binding proteins in human saliva. Biochemical Journal. 1995, vol. 311, pp. 341-347.
Charlton, A. J. et al., “Polyphenol/Peptide Binding and Precipitation,”J. Agric. Food Chem., 50, pp. 1593-1601 (2002); published by American Chemical Society.
Chasin, M., “Biodegradable Polymers for Controlled Drug Delivery,” J.O. Hollinger Editor, Biomedical Applications of Synthetic Biodegradable Polymers CRC, Boca Raton, FL (1995), pp. 1-15.
Hatano, et al., “Size Exclusion Chromatographic Analysis of Polyphenol-Serum Albumin Complexes,” Phytochemistry, 2003, vol. 63, pp. 817-823.
Hyashi, T., “Biodegradable Polymers for Biomedical Uses,” Prog. Polym. Sci 19:4 (1994), pp. 663-700.
Matsuo, A. et al., “Interaction of Peptides Having a Turn Structure with Tannins,”Peptide Science 2001, pp. 205-206, H. Aoyagi (Ed.); The Japanese Peptide Society (2002).
Naurato, et al., “Interaction of Tannin with Human Salivary Histatins,” Journal of Agricultural and Food Chemistry, May 4, 1999, vol. 47, No. 6, pp. 2229-2234.
Tamber, H. et al., “Formulation Aspects of Biodegradable Polymeric Microspheres for Antigen Delivery,” Advanced Drug Delivery Reviews, 57:3 (2005) pp. 351-376.
Zhang, Y.-J. et al., “Association of Tannins and Related Polyphenols with the Cyclic Peptide Gramicidin S,”Chem. Pharm. Bull., 50(2), pp. 258-262 (2002); published by Pharmaceutical Society of Japan.

Affiliated with

Also associated with

Rating

Sustained release formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4249792